Live Breaking News & Updates on Haifa Kathrin Al Ali

Stay updated with breaking news from Haifa kathrin al ali. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

BET inhibitors combined with JAK inhibitors well-tolerated with myelofibrosis

BET inhibitors combined with JAK inhibitors well-tolerated with myelofibrosis
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

San Diego , United States , Mindy Valcarcel , Bydavid Statman , Jakafi Incyte , Haifa Kathrin Al Ali , Bristol Myers Squibb , Krukenberg Cancer Center , University Hospital ,

BMS-986158–Based Combos May Provide Another Viable Treatment Approach in Myelofibrosis

Haifa Kathrin Al-Ali, MD, provides background on the phase 1/2 study of BMS-986158, presents initial efficacy and safety data from the study, and discusses her hope that novel combination regimens like these could achieve the challenging goal of disease modification in myelofibrosis in the future. ....

Haifa Kathrin Al Ali , University Hospital Of Halle Saale , Krukenberg Cancer Center , Translational Oncology , University Hospital , Bms 986158 , Bet Inhibitor , Phase 1 2 Ca011 023 Trial Nct04817007 ,

Dr Al-Ali on the Safety and Efficacy of BMS-986158 Plus Ruxolitinib or Fedratinib in Myelofibrosis

Haifa Kathrin Al-Ali, MD, discusses the safety and efficacy findings from the dose-escalation portion of the phase 1/2 CA011-023 trial of BMS-986158 in combination with ruxolitinib or fedratinib in patients with intermediate- or high-risk myelofibrosis. ....

Haifa Kathrin Al Ali , University Hospital Of Halle Saale , Krukenberg Cancer Center , Translational Oncology , University Hospital ,

Bristol Myers Squibb to Highlight Diversified Approaches and Commitment to Improving Outcomes for Patients with Cancer and Serious Blood Disorders at ASCO, EHA and ICML 2023

First disclosure from Phase 3 COMMANDS study, selected for both ASCO’s official press program and EHA’s plenary session, highlights potential of Reblozyl as first-line treatment of. | May 11, 2023 ....

United States , South Korea , Andrew Wei , Bartl Scott , Jean Marie Michot , Lorettaj Nastoupil , Nizarj Bahlis , Mitsuho Imai , John Mascarenhas , Amit Verma , Kevin Joseph Harrington , David Paul Carbone , Hemophagocytic Lymphohistiocytosis , Heinz Josef Lenz , Farrukh Awan , Husseina Tawbi , Jessica Jiyeong Lin , John Kelly , Amerm Zeidan , Francesco Passamonti , Marcs Raab , Shailender Bhatia , Rafat Abonour , Faisal Faak , Dirk Schadendorf , Rashaun Fleming ,

Bristol Myers Squibb to Highlight Diversified Approaches and Commitment to Improving Outcomes for Patients with Cancer and Serious Blood Disorders at ASCO, EHA and ICML 2023

11.05.2023 - Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, the European Hematology Association (EHA) Congress, and the International Conference on Malignant . ....

United States , South Korea , Amit Verma , Saloman Manier , Alit Taher , Andrew Wei , Hemophagocytic Lymphohistiocytosis , Bartl Scott , Jonathan Spicer , Paul David Harker Murray , Haifa Kathrin Al Ali , Javier Munoz , Javidj Moslehi , Krina Patel , Farrukh Awan , Rafat Abonour , Kevin Joseph Harrington , Melissa Alsina , Lorettaj Nastoupil , Marcs Raab , Jean Marie Michot , Franck Morschhauser , Josephj Sacco , Mitsuho Imai , Dirk Schadendorf , David Paul Carbone ,